Who
Chase C. Leavitt
Officer
Company insider
Files Form 4 as: Officer, Mobia Medical; General Counsel/Secretary, Oncternal Therapeutics; General Counsel/Secretary, Lineage Cell Therapeutics.
In numbers
- Trades disclosed
- 34
- Buys
- 8
- Sells
- 0
- Bought
- $175K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 20 May 2019
- Last trade
- 11 Sep 2026
- Last filed
- 15 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 15 Sep 2026 | MOBI Mobia MedicalMedical Devices | SEC FORM 4 Bought | $21K2,000 at $10.30 | filing |
| 11 Sep 2026filed 15 Sep 2026 | MOBI Mobia MedicalMedical Devices | SEC FORM 4 Bought | $21K2,000 at $10.30 | filing |
| 11 May 2026filed 11 May 2026 | MOBI Mobia MedicalMedical Devices | SEC FORM 4 Bought | $45K3,000 at $15.00 | filing |
| 11 May 2026filed 11 May 2026 | MOBI Mobia MedicalMedical Devices | SEC FORM 4 Bought | $45K3,000 at $15.00 | filing |
| 7 May 2026filed 11 May 2026 | MOBI Mobia Medicaloption or derivative · Medical Devices | SEC FORM 4 Code A | —175,760 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | MOBI Mobia Medicaloption or derivative · Medical Devices | SEC FORM 4 Code A | —175,760 at $0.00 | filing |
| 14 Feb 2024filed 15 Feb 2024 | Oncternal Therapeuticsoption or derivative | SEC FORM 4 Code A | —14,200 at $0.00 | filing |
| 3 Jan 2024filed 5 Jan 2024 | Oncternal Therapeutics | SEC FORM 4 Code F | $5,91911,838 at $0.50 | filing |
| 2 Oct 2023filed 4 Oct 2023 | Oncternal Therapeuticsoption or derivative | SEC FORM 4 Code D | —65,000 | filing |
| 2 Oct 2023filed 4 Oct 2023 | Oncternal Therapeuticsoption or derivative | SEC FORM 4 Code D | —55,519 | filing |
| 2 Oct 2023filed 4 Oct 2023 | Oncternal Therapeuticsoption or derivative | SEC FORM 4 Code D | —28,750 | filing |
| 2 Oct 2023filed 4 Oct 2023 | Oncternal Therapeuticsoption or derivative | SEC FORM 4 Code D | —210,000 | filing |
| 2 Oct 2023filed 4 Oct 2023 | Oncternal Therapeuticsoption or derivative | SEC FORM 4 Code A | —65,000 | filing |
| 2 Oct 2023filed 4 Oct 2023 | Oncternal Therapeuticsoption or derivative | SEC FORM 4 Code A | —55,519 | filing |
| 2 Oct 2023filed 4 Oct 2023 | Oncternal Therapeuticsoption or derivative | SEC FORM 4 Code A | —28,750 | filing |
| 2 Oct 2023filed 4 Oct 2023 | Oncternal Therapeuticsoption or derivative | SEC FORM 4 Code A | —210,000 | filing |
| 2 Oct 2023filed 4 Oct 2023 | Oncternal Therapeuticsoption or derivative | SEC FORM 4 Code A | —235,000 at $0.00 | filing |
| 3 Jul 2023filed 5 Jul 2023 | Oncternal Therapeutics | SEC FORM 4 Code F | $3,71010,305 at $0.36 | filing |
| 13 Apr 2023filed 14 Apr 2023 | Oncternal Therapeutics | SEC FORM 4 Bought | $2,90010,000 at $0.29 | filing |
| 12 Apr 2023filed 14 Apr 2023 | Oncternal Therapeutics | SEC FORM 4 Bought | $4,35015,000 at $0.29 | filing |
News
Financial Review: Owlet (NYSE:OWLT) and Mobia Medical (NASDAQ:MOBI)MOBI · themarketsdaily.com · 19 Oct 2026
0 headlines in the last 90 days name Chase C. Leavitt; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.